While Rocket Pharmaceuticals Inc has underperformed by -1.05%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RCKT rose by 48.45%, with highs and lows ranging from $32.53 to $14.89, whereas the simple moving average jumped by 11.72% in the last 200 days.
On April 02, 2024, Goldman started tracking Rocket Pharmaceuticals Inc (NASDAQ: RCKT) recommending Neutral. A report published by Cantor Fitzgerald on October 24, 2023, Initiated its previous ‘Overweight’ rating for RCKT. Morgan Stanley also rated RCKT shares as ‘Overweight’, setting a target price of $45 on the company’s shares in an initiating report dated February 01, 2023. Canaccord Genuity Initiated an Buy rating on November 08, 2022, and assigned a price target of $53. BTIG Research initiated its ‘Buy’ rating for RCKT, as published in its report on November 01, 2022. Raymond James’s report from July 08, 2022 suggests a price prediction of $22 for RCKT shares, giving the stock a ‘Outperform’ rating. Cowen also rated the stock as ‘Outperform’.
Analysis of Rocket Pharmaceuticals Inc (RCKT)
One of the most important indicators of Rocket Pharmaceuticals Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -50.01% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 7.80, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and RCKT is recording 724.51K average volume. On a monthly basis, the volatility of the stock is set at 4.21%, whereas on a weekly basis, it is put at 3.35%, with a loss of -4.25% over the past seven days. Furthermore, long-term investors anticipate a median target price of $49.33, showing growth from the present price of $25.43, which can serve as yet another indication of whether RCKT is worth investing in or should be passed over.
How Do You Analyze Rocket Pharmaceuticals Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 7.07%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 96.05% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
RCKT shares are owned by institutional investors to the tune of 96.05% at present.
